Lomustine Application Scope

Gleostine® is primarily indicated for the treatment of glioma, including glioblastoma multiforme (GBM) and other malignant brain tumors. It is used for patients with recurrent or difficult-to-treat gliomas, either as monotherapy or as part of combination chemotherapy, particularly when other treatments have limited efficacy.

Lomustine Characteristics

Ingredients: Lomustine
Properties: Oral alkylating agent, crosses blood-brain barrier
Packaging Specification: 10 mg × 10 tablets/box
Storage: Store in a cool, dry place, away from light
Expiry Date: See packaging
Executive Standard: Drug Registration Regulations
Approval Number: NMPA H20140001
Date of Revision: June 2022
Manufacturer: NextSource Biotechnology

Guidelines for the Use of Gleostine

Dosage and Administration:
- Missed Dose: If a dose is missed, administer as soon as possible. Resume monthly dosing from the date of the most recently administered dose.
Adverse Reactions:
- Common Adverse Reactions (≥5%):
  - nausea, vomiting, decreased blood counts, fatigue
- Serious Adverse Reactions:
  - hypersensitivity reactions, severe myelosuppression.
Contraindications: Patients with known severe hypersensitivity to it
or excipients
Precautions:
- Monitor blood counts and liver function during treatment
- Advise patients to inform healthcare provider if pregnant, planning pregnancy, or breastfeeding

Lomustine Interactions

Consult healthcare provider for potential drug interactions

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.